Investors on the bond markets initially reacted with relief to the new data: prices rose and, in return, yields fell. Ten-year US bonds are yielding 2.704 percent after hitting the 2.8 percent threshold in the morning. Two-year bonds yield 2.4321 percent. The yield on ten-year German bonds, which had reached its highest level since 2015 at 0.8 percent, also fell slightly.

Yields had increased significantly in the past few weeks. Since they develop inversely to the courses, there was a crash in these papers, which are supposed to be a haven of security. The prices of US bonds with a term of ten years fell from 101 percent to 91.89 percent during this period – a loss of more than nine percent within six weeks. Such a development takes several years at normal times on the bond market.

At the same time, securities with short maturities sometimes yield higher returns than those with longer maturities. That’s unusual because investors typically demand a higher yield the longer they commit, and is thought to portend a recession.

But where is all the money going? The only beneficiaries right now are gold and silver. The price for a troy ounce (31.1 grams) of the yellow precious metal is currently 1973 dollars, silver costs 25.53 dollars. The gold price has thus broken out of its trading range that has existed since mid-March. Gold continues to defy rising bond yields and real interest rates.

“Most people seem to be saying ‘cash is king’ at the moment,” says capital market expert Thomas Altmann from asset manager QC Partners. That in turn gives hope. “Given the fact that there are still penalty interest rates for holding cash in the euro zone, this situation should not last for too long.”

Look at the chart technique

From a technical point of view, the situation in the German stock market clearly deteriorated in the morning. Investors should currently focus their attention on the underside. The Frankfurt benchmark slipped below last week’s low of 14,027 points. The fact that things went up as a result can also be seen as a good signal in terms of chart technology.

The next important stop on the bottom is 13,680 points. There lies the normal correction of the upside from March 7th to 29th, which ranged from 12,438 points on the downside to 14,925 points according to technical analysis. Normal correction means a fall from the peak by 50 percent of the previous rise.

Look at individual values

Deutsche Bank/Commerzbank: After the US hedge fund Cerberus, the two German financial institutions are losing another major investor. On Monday evening, the investment bank Morgan Stanley offered two blocks of shares in the two major banks, each of more than five percent, from the same investor. This is Capital Group. The packages should bring a total of 1.75 billion euros.

According to the commissioned bank, 116 million Deutsche Bank shares are to be sold at a price of at least EUR 10.98, which is almost eight percent less than the Xetra closing price on Monday. 72.5 million Commerzbank papers are to be placed for EUR 6.55 each, a good six percent below the closing price.

The discount is relatively high, in many cases the discount is five percent. Accordingly, the price of the two shares slipped significantly. Deutsche Bank and Commerzbank titles lose more than eight percent in the Dax and MDax.

Defense stocks: Armor values ​​were again in demand for the individual values. Shares in the Italian armaments group Leonardo rose by up to four percent. Deutsche Bank analysts upgraded the stock to a buy on expectations of higher defense spending in the company’s main markets. Investors also sensed rosy business prospects at Rheinmetall. The titles led the list of MDax winners with an increase of more than three percent, but gave up part of the profits.

Evotec: The Hamburg biotech company grew significantly last year thanks to higher milestone payments from its partnerships. However, the share loses two percent in a weak market environment.

Dermapharm: The Group can look back on the most successful fiscal year in the company’s history. Sales and profit increased significantly. The paper gains 1.7 percent, but returns its gains later. The drug manufacturer also intends to significantly increase the dividend for the past year. The Board of Management and the Supervisory Board propose a distribution of EUR 2.17 (previous year: EUR 0.88) per share,

Here is the page with that Dax coursehere there are current tops & flops in the Dax.